Sonoma Pharmaceuticals (SNOA) Profit After Tax (2010 - 2026)

Sonoma Pharmaceuticals has reported Profit After Tax for 17 years, with the latest figure at -$330000.0 in Q2 2026.

• On a quarterly basis, Profit After Tax rose 73.41% year-over-year to -$330000.0 in Q2 2026; TTM through Jun 2026 was -$2.3 million, a 39.37% increase from a year earlier, with the FY2026 full-year figure at -$3.2 million, up 37.87% from the prior year.
• Profit After Tax was -$330000.0 for Q2 2026 at Sonoma Pharmaceuticals, up from -$581000.0 in the prior quarter.
• The five-year high for Profit After Tax was -$330000.0 in Q2 2026, with the low at -$2.9 million in Q1 2022.
• Average Profit After Tax over 5 years is -$1.1 million, with a median of -$1.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax sank 204.49% in 2022, then soared 73.41% in 2026.
• Over 5 years, Profit After Tax stood at -$1.9 million in 2022, then surged by 55.34% to -$866000.0 in 2023, then plunged by 48.38% to -$1.3 million in 2024, then soared by 36.26% to -$819000.0 in 2025, then jumped by 59.71% to -$330000.0 in 2026.
• The last three Profit After Tax figures came in at -$330000.0 (Q2 2026), -$581000.0 (Q1 2026), and -$819000.0 (Q4 2025), per Business Quant data.